January 19, 2026 — Leads & Copy — Repare Therapeutics Inc. announced that its shareholders have approved the acquisition of all of the company’s issued and outstanding common shares by XenoTherapeutics, Inc. and Xeno Acquisition Corp. The approval was granted at a special meeting of shareholders held today.
The special resolution approving the arrangement was approved by 99.76% of the votes cast by shareholders present in person or represented by proxy at the meeting. This excludes votes required to be excluded pursuant to Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions.
At the meeting, shareholders also approved the following:
- On an advisory and non-binding basis, the compensation to be paid or become payable to the company’s named executive officers that is based on or otherwise relates to the arrangement (99.34%).
- In the event the arrangement is terminated:
- The voluntary liquidation and dissolution of the company (99.75%).
- The appointment of KPMG LLP, or another liquidator of nationally recognized experience, as the liquidator of the company, with authorization for the board of directors to set the liquidator’s remuneration (99.75%).
The arrangement is subject to the approval of the Superior Court of Québec and other customary closing conditions. The court hearing for the final order to approve the arrangement is expected to take place on January 23, 2026. Assuming receipt of the court’s approval and satisfaction of other customary conditions to closing, the completion of the arrangement is expected to occur on or about January 28, 2026.
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company’s clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; and RP-1664, a Phase 1 PLK4 inhibitor.
XenoTherapeutics, Inc. is a Massachusetts-based 501(c)(3) research foundation focused on advancing xenotransplantation through scientific research, clinical development, and public education.
Source: Repare Therapeutics Inc.
